• 1
    American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2002.
  • 2
    Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I. General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104: 274653.
  • 3
    Jha P, Flather M, Lonn E, et al. The antioxidant vitamins and cardiovascular disease: a critical review of epidemiologic and clinical trial data. Ann Intern Med. 1995;123: 86072.
  • 4
    Diplock AT. Antioxidant nutrients and disease prevention. Am J Clin Nutr. 1991;53: S189S93.
  • 5
    Hennekens CH, Gaziano JM. Antioxidants and heart disease: epidemiology and clinical evidence. Clin Cardiol. 1993;16(4 suppl): I10I15.
  • 6
    Maxwell S. Antioxidant vitamin supplements. Update of their potential benefits and possible risks. Drug Safety. 1999;21: 25366.
  • 7
    Clifton PM. Antioxidant vitamins and coronary heart disease risk. Curr Opin Lipidol. 1995;6: 204.
  • 8
    Asplund K. Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review. J Intern Med. 2002;251: 37292.
  • 9
    Tribble DL. Antioxidant consumption and risk of coronary heart disease. Emphasis on vitamin C, vitamin E, and beta-carotene: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;99: 5915.
  • 10
    Shekelle P, Morton S, Hardy M. Effect of Supplemental Antioxidants Vitamin C, Vitamin E, and Coenzyme Q10 for the Prevention and Treatment of Cardiovascular Disease. Evidence Report/Technology Assessment no. 83 (Prepared by Southern California RAND Evidence-Based Practice Center, under contract no. 290-97-0001). AHRQ Publication no. 03-E043. Rockville, Md: Agency for Healthcare Research and Quality; 2003.
  • 11
    McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of the grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet. 2000;356: 122831.
  • 12
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17: 112.
  • 13
    Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273: 40812.
  • 14
    Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352: 60913.
  • 15
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7: 17788.
  • 16
    Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. San Diego, Calif: Academic Press; 1985.
  • 17
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21: 153958.
  • 18
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50: 1088101.
  • 19
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315: 62934.
  • 20
    Leppala JM, Virtamo J, Fogelholm R, et al. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol. 2000; 20: 2305.
  • 21
    De Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group Primary Prevention Project. Lancet. 2001;357: 8995.
  • 22
    Salonen JT, Nyyssonen K, Salonen R, et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Int Med. 2000;248: 37786.
  • 23
    Mark SD, Wang W, Fraumeni JF, et al. Do nutritional supplements lower the risk of stroke or hypertension? Epidemiology. 1998;9: 915.
  • 24
    Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356: 12138.
  • 25
    Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease. Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347: 7816.
  • 26
    Haeger K. The treatment of peripheral occlusive arterial disease with alpha-tocopherol as compared with vasodilator agents and antiprothrombin (dicumarol). Vasc Dis. 1968;5: 199213.
  • 27
    Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342: 15460.
  • 28
    GISSI-Prevenzione Investigators. (Gruppo Italiano per lo Studio della Sopravvianza nell’Infarto Miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354: 44755.
  • 29
    Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997;349: 171520.
  • 30
    MRC/BHF Heart Protection Study Collaborative group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360: 2333.
  • 31
    Haeger K. Letter: vitamin E in intermittent claudication. Lancet. 1974;1: 1352.
  • 32
    Gillilan RE, Mondell B, Warbasse JR. Quantitative evaluation of vitamin E in the treatment of angina pectoris. Am Heart J. 1977;93: 4449.
  • 33
    Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins Probucol Study Group. N Engl J Med. 1997;337: 36572.
  • 34
    Virtamo J, Rapola JM, Ripatti S, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med. 1998;158: 66875.
  • 35
    Rapola JM, Virtamo J, Ripatti S, et al. Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris. Heart. 1998;79: 4548.
  • 36
    Brown BG, Xue-Qiao Z, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345: 158392.
  • 37
    Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288: 243240.
  • 38
    Ness A, Smith GD. Mortality in the CHAOS trial. Cambridge Heart Antioxidant Study. Lancet. 1999;353: 10178.
  • 39
    Singh RB, Niaz MA, Rastogi SS, Rastogi S. Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival-3). Am J Cardiol. 1996;77: 2326.
  • 40
    Sisto T, Paajanen H, Metsa-Ketela T, Harmoinen A, Nordback I, Tarkka M. Pretreatment with antioxidants and allopurinol diminishes cardiac onset events in coronary artery bypass grafting. Ann Thorac Surg. 1995;59: 151923.
  • 41
    Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 1998;12: 34753.
  • 42
    Kaikkonen J, Kosonen L, Nyyssonen K, et al. Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercised-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners. Free Radic Res. 1998;13: 152833.
  • 43
    Wen Y, Cooke T, Feely J. The effect of pharmacological supplementation with vitamin C on low-density lipoprotein oxidation. Br J Clin Pharmacol. 1997;44: 947.
  • 44
    Porkkala-Sarataho E, Salonen JT, Nyyssonen K, et al. Long-term effects of vitamin E, vitamin C, and combined supplementation on urinary 7-hydro-8-oxo-2′-deoxyguanosine, serum cholesterol oxidation products, and oxidation resistance of lipids in nondepleted men. Arterioscler Thromb Vasc Biol. 2000;20: 208793.
  • 45
    Raitakari OT, McCredie RJ, Witting P, et al. Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolemic young adults. Free Radic Biol Med. 2000;28: 11005.
  • 46
    Iino K, Abe K, Kariya S, Kimura H, Kusaba T. A controlled, double-blind study of dl-alpha-tocopheryl nicotinate (Juvela-Nicotinate) for treatment of symptoms in hypertension and cerebral arteriosclerosis. Jpn Heart J. 1977;18: 27783.
  • 47
    Kaikkonen J, Nyyssonen K, Tomasi A, et al. Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study. Free Radic Res. 2000; 33: 32940.
  • 48
    Vivekananthan DP. Use of antioxidant vitamins for the prevention of cardiovascular disease. Lancet. 2003;361: 201723.
  • 49
    Morris CD, Carson S. Routine vitamin supplementation to prevent cardiovascular disease. A summary of the evidence for the U. S. Preventive Services Task Force. Ann Int Med. 2003;139: 5670.
  • 50
    Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282: 105460.
  • 51
    Balk EM, Bonis PA, Moskowitz H, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA. 2002;287: 297382.